AstraZeneca PLC’s top-selling drug Tagrisso (osimertinib) cut the risk of disease recurrence or death by 83% in patients with early stage EGFR mutant non–small cell lung cancer at two years, the first data from the Phase III ADAURA study show.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?